EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide

Karen Schneck iD, Shweta Urva iD

CPT: Pharmacometrics & Systems Pharmacology · 2024-03 · 13 (3) · 494-503

DOI: 10.1002/psp4.13099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 14.02.2024. Verfasst von Karen Schneck und 1 weiteren Autor:innen. Beteiligte Einrichtung: Global PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tirzepatide is a first‐in‐class glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist approved as for the treatment of type 2 diabetes mellitus. A population‐based pharmacokinetic (PK) model was developed from 19 pooled studies. Tirzepatide pharmacokinetics were well‐described by a two‐compartment model with first order absorption and elimination. The tirzepatide population PK model utilized a semimechanistic allometry model to describe the relationship between body size and tirzepatide PK. The half‐life of tirzepatide was ~5 days and enabled sustained exposure with once‐weekly subcutaneous dosing. The covariate analysis suggested that adjustment of the dose regimen based on demographics or subpopulations was unnecessary. The tirzepatide PK model can be used to predict tirzepatide exposure for various scenarios or populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HumansGastric Inhibitory PolypeptideGlucagon-Like Peptide-2 ReceptorHalf-LifeTirzepatide

Substanzen

TirzepatideGastric Inhibitory PolypeptideGlucagon-Like Peptide-2 Receptor

Autor:innen und Institutionen

  • Global PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA.

ORCID-Profile: Karen Schneck, Shweta Urva

Zitieren

APA

Schneck, K., & Urva, S. (2024). Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT: Pharmacometrics & Systems Pharmacology, 13(3), 494-503. https://doi.org/10.1002/psp4.13099

Vancouver

Schneck K, Urva S. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(3):494-503. doi:10.1002/psp4.13099

BibTeX
@article{Schneck2024,
  author = {Schneck, Karen and Urva, Shweta},
  title = {Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  volume = {13},
  number = {3},
  pages = {494--503},
  doi = {10.1002/psp4.13099}
}
Kostenlos starten →